Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02906579 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
A Phase 2 study, sponsored by Cyclerion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02906579 is a Phase 2 study that has completed, run by Cyclerion Therapeutics. The registered enrollment target is 11 participants.
The verdict
NCT02906579, a Phase 2 study, has completed, sponsored by Cyclerion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
To evaluate the impact of escalating doses of IW-1973 on endothelial function \[using EndoPAT to measure fingertip small vessel pulse volume\], blood pressure (BP), and heart rate.
Interventions
- DRUG Matching Placebo
- DRUG IW-1973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-03-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02906579
The ClinicalTrials.gov registry entry for NCT02906579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclerion Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT02906579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02906579 about?
NCT02906579 is a clinical study titled "A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension". To evaluate the impact of escalating doses of IW-1973 on endothelial function \[using EndoPAT to measure fingertip small vessel pulse volume\], blood pressure (BP), and heart rate.
What is the current status of trial NCT02906579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-09. Estimated completion is 2017-03-17.
What interventions are being tested in trial NCT02906579?
The interventions under investigation include: Matching Placebo (DRUG), IW-1973 (DRUG).
Who is sponsoring clinical trial NCT02906579?
This trial is sponsored by Cyclerion Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.